Regeneron Pharmaceuticals (REGN) announced the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Libtayo as monotherapy to treat patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy. The approval is based on positive data from the international, multicenter Phase 3 EMPOWER-Cervical 1 trial.
In November, Libtayo was approved by the European Commission for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.